Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study

Jennbacken, 2006, Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity, Prostate, 66, 1631, 10.1002/pros.20469 Miller, 2010, Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer, J Oncol, 2010, 617421, 10.1155/2010/617421 Moreno, 2005, Circulating tumor cells predict survival in patients with metastatic prostate cancer, Urology, 65, 713, 10.1016/j.urology.2004.11.006 Tombal, 2003, Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy, Prostate, 56, 163, 10.1002/pros.10237 Davis, 2008, Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer, J Urol, 179, 2187, 10.1016/j.juro.2008.01.102 de Bono, 2008, Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer, Clin Cancer Res, 14, 6302, 10.1158/1078-0432.CCR-08-0872 Hortobagyi, 1996, Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases, N Engl J Med, 335, 1785, 10.1056/NEJM199612123352401 Rosen, 2003, Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial, Cancer, 98, 1735, 10.1002/cncr.11701 Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141 Rosen, 2004, New generation of bisphosphonates: broad clinical utility in breast and prostate cancer, Oncology (Williston Park), 18, 26 Berenson, 2001, Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases, Cancer, 91, 1191, 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0 Major, 2003, Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone [abstract], Proc Am Soc Clin Oncol, 22, 762 Morgan, 2010, First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial, Lancet, 376, 1989, 10.1016/S0140-6736(10)62051-X Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285 Zaghloul, 2010, A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer, Int J Clin Oncol, 15, 382, 10.1007/s10147-010-0074-5 Hoshi, 2010, The impact of Zoledronic acid therapy in survival of bladder cancer patients with bone metastasis [abstract], A1712 Dearnaley, 2009, Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials, Lancet Oncol, 10, 872, 10.1016/S1470-2045(09)70201-3 Coleman, 2010, The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer, Br J Cancer, 102, 1099, 10.1038/sj.bjc.6605604 Dearnaley, 2009, Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials, Lancet Oncol, 10, 872, 10.1016/S1470-2045(09)70201-3 Eidtmann, 2010, Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study, Ann Oncol, 21, 2188, 10.1093/annonc/mdq217 Fournier, 2010, How do bisphosphonates inhibit bone metastasis in vivo?, Neoplasia, 12, 571, 10.1593/neo.10282 van der Pluijm, 1996, Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro, J Clin Invest, 98, 698, 10.1172/JCI118841 Boissier, 2000, Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases, Cancer Res, 60, 2949 Wood, 2002, Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid, J Pharmacol Exp Ther, 302, 1055, 10.1124/jpet.102.035295 Senaratne, 2000, Bisphosphonates induce apoptosis in human breast cancer cell lines, Br J Cancer, 82, 1459, 10.1054/bjoc.1999.1131 Ory, 2005, Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, Cancer, 104, 2522, 10.1002/cncr.21530 Banys, 2013, Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial, BMC Cancer, 13, 480, 10.1186/1471-2407-13-480 de Bono, 2008, Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer, Clin Cancer Res, 14, 6302, 10.1158/1078-0432.CCR-08-0872